Feb 12, 2021 / 04:00PM GMT
Seamus Christopher Fernandez - Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals
All right. Good morning, everyone. I believe we are now live. And this is the second day of Guggenheim's oncology days. I can't say that we can't call it the oncology day anymore because it's now a 2-day conference because there are so many companies really drilling into oncology. But I'm really pleased to be joined here today with Anne White, who you see on the screen. Anne is the Senior Vice President and President of Lilly Oncology. And also, we have Jake Van Naarden, who many of you know, Jake is CEO of Loxo Oncology, which is one of the acquired subsidiaries of Eli Lilly.
Questions and Answers:
Seamus Christopher Fernandez - Guggenheim Securities, LLC, Research Division - Senior Analyst of Global PharmaceuticalsSo just to jump right in, we only have 25 minutes, so there's plenty to get to. Anne maybe just to kick us off just from a big picture strategy perspective, if you don't mind, just love to maybe start off on your thinking